Life Sciences

Barron exhorts GSK scientists to take ‘smart risks’

July 22, 2019

Hal Barron has detailed efforts to embolden GlaxoSmithKline scientists to take “smart risks” when developing drugs. The culture change is part of an effort to stop the fear of failure from pushing GSK researchers to make conservative decisions. Talking to the Financial Times, Barron discussed..

Partnering for a global healthcare ecosystem

July 22, 2019

Japan has become the world’s test bed for the treatment of the elderly by virtue of being the world’s longest-lived country. Fifty years ago it is reported to have had just 327 centenarians. In 2017, the total reached 67,824, the largest per capita ratio in..

Pfizer’s keys to juggling 8 U.S. launches? Organization, accountability, clear goals

July 22, 2019

Think you’re busy? Take a look at Pfizer’s commercial team for oncology, which is currently launching four new drugs, three new indications for older drugs, and a biosimilar. And that’s just in the U.S. It’s taken some serious internal organizing on Pfizer’s part, but so..

Genmab’s Huge IPO Raises €450M to Develop Antibody Drugs

July 22, 2019

The Danish biotech Genmab has made a big splash on the Nasdaq, raising a €450M ($506M) IPO to fuel its antibody drug programs in cancer, autoimmune diseases, and more. This IPO is one of the biggest in biotech history, behind the whopping €530M Nasdaq entry from US..

Is Novartis’ sunny Sandoz forecast realistic?

July 19, 2019

Novartis has spent much of the last year overhauling its generics division, Sandoz, by increasing its focus on hard-to-make drugs and doubling down on its use of digital technologies to improve everything from drug development to commercialization. Those efforts are paying off, the company said..

Takeda shops €1.5B European drug sale: report

July 19, 2019

Takeda’s ax is about to fall again, this time on some over-the-counter and off-patent prescription drugs in Western Europe. The Japanese pharma, still working to pay down debt it incurred for its Shire buy, tapped J.P.Morgan to help it find a buyer—or buyers—for some European..

Gilead CEO O’Day continues top-level revamp with two more exec exits

July 18, 2019

New Gilead CEO Daniel O’Day has already replaced some key leaders at the company, but he’s not stopping there with the executive overhaul. Wednesday, the Big Biotech said it would bid farewell to Gregg Alton, its chief patient officer, and Katie Watson, its EVP of..

Immusoft names former Amgen biologics head as chief scientific officer

July 18, 2019

Immusoft has named Robert Hayes as its chief scientific officer. Hayes, the former head of biologics at Amgen, joins the cell therapy startup as it works to move a treatment for mucopolysaccharidosis type I into clinical testing. Seattle-based Immusoft hired Hayes from Phylogica, an Australian..

Pharmaceutical pricing – it’s political

July 16, 2019

Dr Joe Zammit-Lucia on why it is becoming increasingly import for pharma companies to develop new approaches to pricing that have political resonance Some months ago, I was speaking to the chairman of a major UK corporation. He told me that he had just come..

Boehringer buys up cancer vaccine player, eyes oncology combo strategy

July 16, 2019

German pharma Boehringer Ingelheim is putting a few hundred million euros on the table to snap up Swiss cancer biotech Amal Therapeutics. BI gets access to Amal’s so-called KISIMA platform, which uses peptide/protein-based vaccination tech aimed at treating lung and gastrointestinal cancers. The private biotech’s..

CLIENT PORTAL